TOKYO -- Japan's Fujifilm has inked a patent licensing agreement with China's Zhejiang Hisun Pharmaceutical involving anti-influenza drug Avigan, which has been used to treat Ebola.
The Fujifilm Holdings unit said Wednesday that the Chinese drugmaker may use patents on the effective ingredient of Avigan -- devised by fellow Fujifilm group unit Toyama Chemical -- to develop, produce and market a flu treatment in China. The group is granting the license to another company for the first time.
Unlike most other anti-flu drugs, Avigan blocks viral gene replication in cells to prevent their propagation.
Fujifilm will receive a lump sum as well as royalties when Zhejiang Hisun introduces the product to the market following clinical trials.
Avigan, approved in Japan in 2014 as an anti-flu drug, has been selected as part of the Japanese government's emergency grant aid for fighting Ebola virus disease in Guinea.